BioMarin Settles Patent Dispute, Gains Royalties on Ascendis Drug

Zacks Investment Research··USEUBR·Read original
3▲1 ▼1Impact / 5
Summary · why it matters

BioMarin Pharmaceutical has settled its patent disputes with Ascendis Pharma over Yuviwel, turning a competitive threat into a royalty-bearing asset. Under the agreement, Ascendis will pay BioMarin royalties of 20% of annual net sales in the United States and 18% in the European Union, Brazil, and South Korea, from the first commercial sale in each territory through May 20, 2030. The settlement resolves all pending lawsuits and grants Ascendis a non-exclusive worldwide license to certain patents. Yuviwel, which launched in April, generated €8 million in its first quarter and had enrolled over 220 patients by July 31. However, BioMarin still faces potential competition from BridgeBio Pharma's infigratinib, which could launch in mid-2027.

Impact on assets 3

Biotech & Genomic Medicine± Mixed · 2 stocks
Biomarin Pharmaceutical Inc
BMRN
▲ PositiveRegulationrelevance

Settled all patent lawsuits with Ascendis, converting a competitive threat into 20%/18% royalties on Yuviwel sales through May 2030.

BridgeBio Pharma Inc
BBIO
▼ NegativeCompetitionrelevance

Named as a potential competitor whose infigratinib could launch mid-2027, threatening BioMarin's royalty-bearing Yuviwel franchise.

Health Care▲ · 1 stocks
© 2026 MarketIVNews